statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

Organon (NYSE: OGN), a global healthcare company with a focus on womens health, will release its second quarter 2024 financial results on August 6, 2024, prior to the companys webcast and conference...

Organon & Co. Is a Trending Stock: Facts to Know Before Betting on It

Organon (NYSE: OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the...

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia and Xgeva (denosumab) Biosimilar Candidate HLX14

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an...

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

Organon (NYSE: OGN) (Organon), a global healthcare company with a focus on womens health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary...

Organon Announces Proposed $1.0 Billion Senior Notes Offering

Organon Beats On Q1, Women's Health Leads the Charge

Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
read more...

Organon Reports Results for the First Quarter Ended March 31, 2024

Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2024. 'We entered this year with a clear focus: to deliver our 2024 financial targets while staying true to our...

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

Organon (NYSE: OGN), a global healthcare company with a focus on womens health, will release its first quarter 2024 financial results on May 2, 2024, prior to the companys webcast and conference call...

Phase 3 Comparative Clinical Study of Prolia and Xgeva (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia and Xgeva (denosumab) biosimilar HLX14 met the...

Experts say Medicaid rebate change is behind inhaler price cuts

Lauren Clason | (TNS) CQ-Roll Call
A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma...

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Volume	987,601.00
52-Wk High	$24.08
52-Wk Low	$10.84

OGN Organon & Co.

About

Feed

News

Sentiment

Earnings

Fundamentals